Abstracts Archive - Page 2272 of 2425 - ACR Meeting Abstracts

Abstract Number: 2246 • 2012 ACR/ARHP Annual Meeting
Real World Experience with Belimumab in the Management of Systemic Lupus Erythematosus (SLE): A Single Center, Observational, Post-Marketing Study
Susan S. Kim¹, Tanya Pavri¹, Kyriakos A. Kirou², Jane Salmon¹ and Doruk Erkan¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: With the recent FDA approval of belimumab, clinicians are faced with adjusting their SLE treatment paradigm. The purpose of this study was to examine…
Abstract Number: 2247 • 2012 ACR/ARHP Annual Meeting
The First Report of Desensitization to Trimethoprim/Sulfamethoxazole in Patients with Systemic Lupus Eryhtematosus
Yasuhiro Suyama¹, Mitsumasa Kishimoto², Hiroto Nakano³, Ken-ichi Yamaguchi¹, Hisanori Shimizu⁴, Ryo Rokutanda⁴, Chisun Min², Yuri Ohara⁴, Yoichiro Haji², Kazuo Matsui⁵, Akira Takeda⁶, Yukio Matsui⁷ and Masato Okada⁷, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ³Department of Rheumatology, Kameda Medical Center, Kamogawa City, Japan, ⁴Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ⁶Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, ⁷Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Trimethoprin-sulfamethoxazole (TMP/SMX) is the most effective and widely used prophylactic medication in immunocompromised patients. Some diseases are well-known to cause allergic reactions including human…
Abstract Number: 2248 • 2012 ACR/ARHP Annual Meeting
Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) Identified As a Novel Biomarker for Systemic Lupus Erythematosus (SLE)
Tetsuji Sawada¹, Kazuhiro Nakamura², Ryunosuke Ohkawa², Aki Shoji¹, Koichiro Tahara¹, Haeru Hayashi¹, Eri Kimura¹, Koji Igarashi³, Junken Aoki⁴ and Yutaka Yatomi⁵, ¹Rheumatology, Tokyo Medical University, Tokyo, Japan, ²Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan, ³AIA Research Group, TOSOH Corporation, Kanagawa, Japan, ⁴Department of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan, ⁵Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Lysophosphatidylserine (LPS), which is a degraded form of phosphatidylserine (PS), is an acidic lyso-glycerophospholipid, similar to lysophosphatidic acid (LPA). LPS is known to mediate…
Abstract Number: 2249 • 2012 ACR/ARHP Annual Meeting
Comparison of Mycophenolate Mofetil and Intravenous Cyclophosphamide As Induction Therapy in Korean Patients with Lupus Nephritis
Dong-Jin Park¹, Kyung-Eun Lee¹, Tae-Jong Kim¹, Yong-Wook Park¹ and Shin-Seok Lee², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: Although intravenous cyclophosphamide (IVC) pulses are generally accepted as standard therapy for induction treatment of active proliferative lupus nephritis (LN), several clinical trials have…
Abstract Number: 2250 • 2012 ACR/ARHP Annual Meeting
A Clinical Analysis of Adult Patients with Autoimmune- and Infection-Associated Hemophagocytic Lymphohistiocytosis
Min W. So¹, Bon S. Koo¹, You J. Kim¹, Yong-G Kim¹, Wook J. Seo², Chang-K Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially life-threatening disease. Secondary HLH is associated with various clinical conditions, including infections, malignancies, and autoimmune diseases.…
Abstract Number: 2251 • 2012 ACR/ARHP Annual Meeting
High Sensitivity C-Reactive Protein, Disease Activity and Cardiovascular Risk Factors in Systemic Lupus Erythematosus
Chi Chiu Mok¹, Daniel Birmingham², Ling Yin Ho¹ and Brad H. Rovin³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Medicine, Ohio State University Medical Center, Columbus, OH, ³Division of Nephrology, Ohio State University Medical Center, Columbus, OH

Background/Purpose: To study the level of high-sensitivity C-reactive protein (hsCRP) and its relationship with disease activity, damage and cardiovascular risk factors in patients with systemic…
Abstract Number: 2252 • 2012 ACR/ARHP Annual Meeting
Epratuzumab-Treated Systemic Lupus Erythematosus Patients Report Improvements in Health-Related Quality of Life: Final Results from an Open-Label Extension Study (SL0006)
V. Strand¹, K. Hobbs², D.J. Wallace³, K. Kalunian⁴, B. Kilgallen⁵, E. Nikaï⁶, W.A. Wegener⁷ and D.M. Goldenberg⁸, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Denver Arthritis Clinic, Denver, CO, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴UCSD School of Medicine, La Jolla, CA, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Brussels, Belgium, ⁷Immunomedics Inc, Morris Plains, NJ, ⁸Centre for Molecular Medicine and Immunology, Morris Plains, NJ
Background/Purpose: Epratuzumab, a monoclonal antibody targeting CD22, is in development for the treatment of systemic lupus erythematosus (SLE). Two randomized controlled trials (RCTs): ALLEVIATE 1…
Abstract Number: 2253 • 2012 ACR/ARHP Annual Meeting
Metabolic Syndrome Is Not Only a Risk Factor for Cardiovascular Events in Systemic Lupus Erythematosus but Also Associated with Cumulative Organ Damage: A Cross-Sectional Analysis of 311 Patients
Semra Ertan-Demir¹, Bahar Artim-Esen², Yasemin Sahinkaya², Özlem Pehlivan², Nilüfer Alpay-Kanitez², Ahmet Omma², Burak Erer², Sevil Kamali², Ahmet Gul², Orhan Aral², Lale Ocal² and Murat Inanc², ¹Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased rates of cardiovascular (CV) events that are one of the major causes of mortality. In addition…
Abstract Number: 2254 • 2012 ACR/ARHP Annual Meeting
Discoid Lupus in Patients with Systemic Lupus Erythematosus
Ghassan AlJohani¹, Dominique Ibanez², D. D. Gladman¹ and Murray B. Urowitz², ¹Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Discoid lupus lesions occur in 20% of patients with SLE at some point in their disease course, and are often resistant to therapy.…
Abstract Number: 2255 • 2012 ACR/ARHP Annual Meeting
Apolipoprotein B Containing Lipoprotein Subclasses and Subclinical Atherosclerosis in Patients with Systemic Lupus Erythematosus (SLE)
Adnan Kiani¹, Hong Fang¹, Ehtisham Akhter², Carmen Quiroga³, Nancy Simpson³, Petar Alaupovic³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Oklahoma Medical Research Foundation, Oklahoma, OK
Background/Purpose: Traditional classification in lipid biology using HDL, LDL and VLDL does not provide information on lipoprotein function. Apolipoproteins, (which are protein components of plasma…
Abstract Number: 2256 • 2012 ACR/ARHP Annual Meeting
A Population of IL-21 Producing CD4⁺ T Cells Correlates with Disease Damage in Systemic Lupus Erythematosus (SLE) Patients
Babak Noamani¹, Stacey Morrison², Dafna D. Gladman³, Jorge Sanchez-Guerrero⁴, Murray B. Urowitz⁵, Joan E. Wither⁶ and Carolina Landolt-Marticorena⁷, ¹Genetics and developmental biology, Toronto Western Research Institute, Toronto, ON, Canada, ²Div Rheumatology Rm MP-10-304, The Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴UHN Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: SLE mice models implicate IL-21, a T cell-derived cytokine, in disease pathogenesis with cytokine over-expression promoting the development of auto-antibodies and lupus-like clinical syndromes.…
Abstract Number: 2257 • 2012 ACR/ARHP Annual Meeting
Association of Low Vitamin D with High Disease Activity in an Australian Systemic Lupus Erythematosus Cohort
Kristy S. Yap¹, Alberta Y. Hoi² and Eric F. Morand², ¹Rheumatology, Monash Medical Centre, Clayton, Australia, ²Centre for Inflammatory Diseases, Monash University, Melbourne, Australia
Background/Purpose: Previous cross-sectional studies suggest that low vitamin D may be associated with higher disease activity in SLE. Vitamin D status varies with geographic location…
Abstract Number: 2258 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Total Joint Replacement in Systemic Lupus Erythematosus Patients with Avascular Necrosis
Jennifer Lee¹, Dae-Jun Kim¹, Jae Ho Lee¹, Seung Min Jung¹, Seung-Ki Kwok¹, Ji Hyeon Ju², Kyung-Su Park¹, Sung-Hwan Park¹ and Ho-Youn Kim¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea, ²Rheumatology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea
Background/Purpose: Avascular necrosis (AVN) is a common manifestation in patients with systemic lupus erythematosus (SLE) and is associated with significant morbidity. A number of studies…
Abstract Number: 2259 • 2012 ACR/ARHP Annual Meeting
Limitations of Current Treatment for Systemic Lupus Erythematosus: A Patient and Physician Survey
V. Strand¹, C. Galateanu², S. Lobosco³, D.S. Pushparajah², J. Sayers⁴ and R.F. van Vollenhoven⁵, ¹Stanford University, Portola Valley, CA, ²UCB Pharma, Brussels, Belgium, ³Adelphi Real World Ltd., Macclesfield, United Kingdom, ⁴Adelph Real World Ltd., Macclesfield, United Kingdom, ⁵Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Current SLE treatment regimens follow an ‘add-on' paradigm: typically, therapies are added as the activity of a patient's disease increases. Most current treatments, particularly…
Abstract Number: 2260 • 2012 ACR/ARHP Annual Meeting
Serum DNAse I Anti DNAse I Antibodies , CRP and Antibodies to CRP Relation to Disease Activity in Systemic Lupus Eryhtematous: Longitudinal Studies
Ramnath Misra¹, Avadesh Pratap², Amit Singh¹ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunlogy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Technician, Lucknow, India
Background/Purpose: Defective clearance of both nuclesomes and immune complexes has been suggested to intiate and perpetuate the disease. Defects in DNAse I gene in mice have shown SLE like symptoms,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].